Physician profile
James D Ladd
NPI 1790771244
$10,003.80
in general payments reported to CMS, 2019-2025
45 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $1,123 · 2021: $1,813 · 2022: $1,518 · 2023: $1,601 · 2024: $1,246 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,184.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,061.31 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $1,022.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $815.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $713.72 | 2019-2025 | Breztri, Nexium, Airsupra |
| Glaxosmithkline, LLC. | $708.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $655.26 | 2019-2025 | |
| Abbvie INC. | $467.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $463.74 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $454.52 | 2019-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $418.43 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $376.16 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $324.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.59 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $245.45 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $233.66 | 2021-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $162.94 | 2019-2024 | Octrode |
| Bayer Healthcare Pharmaceuticals INC. | $153.24 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $138.78 | 2022-2024 | Eliquis |
| Radius Health, INC. | $115.83 | 2019-2023 | Tymlos |
| Eisai INC. | $113.46 | 2020-2025 | |
| Exact Sciences Corporation | $95.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $85.29 | 2021 | |
| Daiichi Sankyo INC. | $84.22 | 2019-2024 | Injectafer |
| Allergan, INC. | $76.68 | 2019-2020 | |
| Amarin Pharma, INC. | $64.29 | 2019-2021 | |
| Esperion Therapeutics, INC. | $61.98 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $53.94 | 2024-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $49.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $39.58 | 2019-2021 | |
| Inari Medical, INC. | $37.95 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Paratek Pharmaceuticals, INC. | $37.36 | 2023 | Nuzyra |
| Si-Bone, INC. | $34.50 | 2024 | |
| Ironwood Pharmaceuticals, INC | $34.29 | 2020 | |
| Antares Pharma, INC. | $33.85 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $32.48 | 2023 | Gemtesa |
| Ibsa Pharma INC. | $31.19 | 2021-2024 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $23.92 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $22.22 | 2025 | Symbravo |
| Vbi Vaccine (Delaware) INC. | $21.56 | 2023 | Prehevbrio |
| Phathom Pharmaceuticals, INC. | $18.79 | 2024 | Voquezna |
| Nevro Corp. | $17.48 | 2023 | Senza |
| Adlon Therapeutics L.P. | $16.37 | 2020 | |
| Genentech USA, INC. | $14.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.